The question of whether Krystal Biotech can reach $400 has a concrete origin. In mid-August 2026, RBC Capital Markets initiated coverage with an Outperform rating and a $400 price target, citing blockbuster potential for the company's lead product and its ophthalmology pipeline. That target sits meaningfully above the stock's recent close near $363.84, making it a realistic but still unproven milestone rather than a figure already achieved.
Krystal Biotech is a commercial-stage biotechnology company specializing in genetic medicines. Its flagship therapy, VYJUVEK (beremagene geperpavec), is a topical gene therapy approved to treat dystrophic epidermolysis bullosa (DEB), a rare and severe skin disorder. The company has expanded commercialization of VYJUVEK into Germany, France, and Japan, and secured United Kingdom approval in May 2026.
The company's proprietary platform uses a modified herpes simplex virus type 1 (HSV-1) to deliver genes across multiple organ systems, enabling non-invasive applications such as gels, eye drops, and inhaled mists. This platform underpins a broad pipeline spanning ophthalmology, respiratory disease, and oncology.
KRYS trades at roughly $364 with a market capitalization near $10.8 billion and a price-to-earnings (P/E) ratio around 45. Revenue for the quarter ended June 30, 2026 reached $119.2 million, up 24% year over year, while net income grew 43% to $54.8 million. Gross margins run near 95%, an unusually high level that reflects the company's in-house manufacturing.
Financially, Krystal Biotech is in a strong position. The company held about $845.6 million in cash and short-term investments against minimal debt of under $9 million, giving it ample runway to fund clinical development without dilutive capital raises.
Several factors could support a move toward $400. First, VYJUVEK continues to grow, with cumulative net product revenue surpassing $965 million since launch. RBC projects the therapy could reach $1 billion in peak annual sales by 2033, with international launches representing the next phase of growth.
Second, the pipeline offers meaningful catalysts. KB801, a gene therapy for neurotrophic keratitis, is viewed by RBC as potentially the company's next major opportunity, with a projected $2.1 billion peak sales opportunity by 2030. Data readouts for ocular DEB, cystic fibrosis, and other programs in the second half of 2026 and into 2027 could re-rate the stock.
Obstacles remain. The valuation is demanding: a P/E near 45 leaves little room for earnings disappointments or slower-than-expected adoption. The company also depends heavily on a single approved product, meaning pipeline setbacks would weigh disproportionately on sentiment.
Insider activity has leaned toward selling, with several executives reducing positions in recent months, a signal some investors interpret cautiously. Wolfe Research initiated coverage with a Hold rating in August 2026, suggesting at least some analysts see current levels as adequately reflecting near-term growth. A break above the 52-week high near $382.54 is also not guaranteed and could act as a technical hurdle.
The Street consensus is a "Strong Buy," with an average price target of about $385, according to data compiled by S&P Global. The range is wide: the highest target, from Jefferies, reaches $474, while the lowest sits near $284. RBC's $400 target and TD Cowen's $403 both point above the current price, while others such as H.C. Wainwright's $361 and Bank of America's $392 bracket the stock more closely. This dispersion underscores that $400 is plausible under favorable execution but not a consensus certainty.
From a technical analysis perspective, the stock's prior record near $382.54 serves as the most important resistance level. A sustained close above that zone would put $400, a clean psychological round number, within reach. On the downside, the $330-to-$335 area has acted as a support level in recent months following the stock's strong run from a 52-week low near $136.73.
For traders monitoring momentum in names like Krystal Biotech, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to track changing conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior, market conditions, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening alone.
A move to $400 for Krystal Biotech appears realistic but not assured. The stock would need to clear its 52-week high near $382.54 and extend into new all-time territory, roughly a 10% advance from recent levels. Supporting that path are accelerating revenue, exceptional gross margins, a cash-rich balance sheet, and a pipeline with potentially transformative catalysts. Working against it are a premium valuation, single-product concentration, ongoing insider selling, and mixed analyst conviction. Investors should watch upcoming pipeline data readouts, international VYJUVEK launch metrics, and whether the stock can hold above its prior highs as the key variables determining the path to $400.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To KRYS | 1D Price Change % | ||
|---|---|---|---|---|
| KRYS | 100% | +0.42% | ||
| VCYT - KRYS | 44% Loosely correlated | -2.76% | ||
| AXON - KRYS | 43% Loosely correlated | +0.10% | ||
| ACAD - KRYS | 42% Loosely correlated | +0.32% | ||
| REPL - KRYS | 39% Loosely correlated | -2.42% | ||
| CADL - KRYS | 39% Loosely correlated | -6.93% | ||
More | ||||